Document is current

Article History

Received: 9 January 2025

Accepted: 17 June 2025

First Online: 7 July 2025

Declarations

:

: A.H-C. has served as a speaker for Sanofi, Takeda, Janssen, Bristol Myers Squibb, AbbVie, and Roche, is an advisor for Sanofi, Takeda, Bristol Myers Squibb, Celgene, and Janssen, and has received research grants from Janssen, Bristol, Takeda, MSD, AstraZeneca, and Roche. R.S. has received conference fees from AbbVie, Eli Lilly, and Roche. M.Z. has received conference fees from Bristol Myers Squibb, Janssen, Roche, and Takeda; support for attending meetings from Sandoz, Amgen, AbbVie, Teva, and Pint Pharma; honoraria from Takeda, AbbVie, AstraZeneca, Teva, and Sandoz; and has participated on the advisory board for Takeda, Janssen, and Merck. S.R-V. has received honoraria from Roche and serves on the advisory board for Takeda. Z.H. is an employee of Takeda Pharmaceuticals and holds Takeda shares. A.K. has received honoraria from Takeda, Amgen, and Janssen, and serves as a member of a board of directors and advisory committee of Novartis.

: The study was conducted according to the Declaration of Helsinki and the International Conference on Harmonization Guidelines on Good Clinical Practice and was approved by the relevant Independent Ethics Committee/Institutional Review Boards at each center.

: All patients provided written informed consent.